In-vivo Dosimetry and Radiation Cataract in Brachytherapy Patients

  • Ana Pitskhelauri Georgian Technical University, Tbilisi, Georgia
  • Irine Gotsiridze Georgian Technical University, Tbilisi, Georgia
Keywords: brachytherapy, in-vivo dosimetry, radiation, cataract, patients

Abstract

Radiation cataract causes partial opacity or cloudiness in the crystalline lens and results from damaged cells covering the posterior surface of the lens. Symptoms can appear as early as one or two years following high-dose exposure and many years after exposure to lower doses. Cataract is a frequent complication of brachytherapy when treated melanoma with localization on the face, nearby with eyes. Radiation Protection and International Commission on Radiological Protection assumptions that a radiation dose of at least 2 Gy is associated with increased cataract risk. For the protection of eyes is used shielding with lead plates in many clinics in the world in pair with in-vivo dosimetry for monitoring. There are several technologies for in-vivo dosimetry. One of them is OSL (optically stimulated luminescence) technology, which is practiced at at Fridon Todua Named Research Institute of Clinical Medicine, Tbilisi, Georgia. For in-vivo dosimetry is used special nanoDot dosimeters. They are designed for use in single point radiation assessment applications. Due to theirs small size, they do not affect the quality of the treatment. The nanoDot dosimeters are wireless and radiolucent. Brachytherapy in Fridon Todua Named Research Institute of Clinical Medicine has been introduced since 2018. During the period 2018-2020, in-vivo dosimetry was carried out in patients with melanoma located on the face in 689 fractions of radiation therapy, including 236 in 2018, 201 in 2019 and 252 in 2020. According to the results of dosimetry monitoring, the risk of cataract occurrence was revealed in only 5 patients (22.7%) in 2018, 2 patients (12.5%) in 2019 and 4 patients (14.8%) in 2020. This risk has been minimized by a dose correction within the limits to allow successful treatment.

References

. Neriishi K, Nakashima E, Minamoto A, Fujiwara S, Akahoshi M, Mishima HK, Kitaoka T, Shore R: Postoperative cataract cases among atomic bomb survivors: Radiation dose response and threshold. Radiation Research 2007.

. Madan M Rehani. Radiation and cataract. Et al. Ratiat Prot Dosimetry. 2011.

. Renu Sharma, Paul A. Jursinic. In-vivo measurements for high dose rate brachytherapy with optically stimulated luminescent dosimeters. The International Journal of Medical Physics Research and Practice “Medical Physics”. University of California at Davis. https://doi.org/10.1118/1.4811143 2013.

. Paul A. Jursinic. Changes in optically stimulated luminescent dosimeter (OSLD) dosimetric characteristics with accumulated dose. The International Journal of Medical Physics Research and Practice “Medical Physics”. University of California at Davis. https://doi.org/10.1118/1.3267489 2009.

Published
2021-11-18
How to Cite
Pitskhelauri, A., & Irine Gotsiridze. (2021). In-vivo Dosimetry and Radiation Cataract in Brachytherapy Patients. International Journal of Applied Sciences: Current and Future Research Trends , 12(1), 37-42. Retrieved from https://ijascfrtjournal.isrra.org/index.php/Applied_Sciences_Journal/article/view/1175
Section
Articles